By Katherine Hamilton

Trevi Therapeutics' shares rose after it shared positive results for a chronic cough treatment.

The stock gained 61% to $6.91 Monday morning, at one point touching a 52-week high of $7.39. It has nearly tripled in value over the past three months.

The New Haven, Conn., biopharmaceutical company shared positive topline results from a Phase 2a trial of Haduvio for the treatment of patients with refractory chronic cough. Haduvio met the primary endpoint by reducing cough frequency by 57% when adjusted for placebo results, which was statistically significant, Trevi said.

Haduvio was effective for trial participants with both severe and moderate coughs.

The results expand Haduvio's base of clinical support to a second chronic cough setting, Oppenheimer analyst Leland Gershell said in a note. Gershell expects Trevi to begin formulating Phase 3 plans.

D. Boral Capital analyst Jason Kolbert said the findings show Haduvio could be a first-in-class treatment for refractory chronic cough, which currently has no approved therapies in the U.S.

Merck has been developing a treatment for chronic cough called gefapixant, but the drug has struggled to gain Food and Drug Administration approval due to concerns about its efficacy. Haduvio's latest results in reducing cough frequency demonstrate that efficacy likely won't be an issue for Trevi, Kolbert said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

March 10, 2025 10:15 ET (14:15 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.